Jazz Pharmaceuticals plc
No SEC Form 4 filings for $JAZZ in the last 30 days.
UBS upgraded Jazz Pharmaceuticals (JAZZ) from neutral to buy and raised its price target to $307 from $188 on May 19, citing expectations for faster commercialization of zanidatamab (Ziihera). The move precedes an Aug. 25 FDA PDUFA decision. UBS forecasts peak Ziihera sales of about $3.1B and 2026-2030 revenue/EPS CAGR of 10%/11%.
Jazz Pharmaceuticals plc has filed a Form 144 with the SEC, indicating a proposed sale of securities. The filing details the sale of 2,741 shares of common stock with an aggregate market value of $662,143.37 by an individual through Morgan Stanley Smith Barney LLC, acquired via a stock option exercise on May 22, 2026. This notice confirms that the person selling the securities does not know of any material adverse information about the issuer that has not been publicly disclosed.
Jazz Pharmaceuticals experienced an 8.5% rise after reporting a significant rebound in Q1 2026 profits and receiving Priority Review from the FDA for its oncology drug, Ziihera. The company swung from a net loss to a net income of US$293.1 million, with earnings per share reaching US$4.43. This positive development, particularly Ziihera's potential in HER2-positive gastric cancer, is crucial for Jazz Pharmaceuticals as it aims to expand its oncology portfolio and mitigate patent pressures on its sleep franchise.
